Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track AZN with free AI briefings, catalyst countdowns, and dilution alerts.

AZN · AstraZeneca PLC

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$8.2B Cash on Hand
CF+ Cash Runway
0.2% Short Interest
$208.07 Analyst Target (12)
Follow AZN by email Get an email when AZN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about AZN, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Benralizumab
FDA approved Nov 2017 · Fasenra
Asthma Phase 4 · NCT03953300 Completed
Rosuvastatin
FDA approved Aug 2003 · Crestor
Hypercholesterolemia Phase 3 · NCT07930507 Not yet recruiting
Olaparib
FDA approved Dec 2014 · Lynparza (discontinued)
Relapsed Ovarian Cancer Phase 3 · NCT03534453 Completed
Acalabrutinib
FDA approved Oct 2017 · Calquence
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Phase 3 · NCT05057494 Active not recruiting
Anifrolumab
FDA approved Jul 2021 · Saphnelo
Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus… Phase 3 · NCT07691970 Recruiting
Selumetinib
FDA approved Apr 2020 · Koselugo
Neurofibromatosis 1 Phase 3 · NCT04924608 Active not recruiting
Tezepelumab
FDA approved Dec 2021 · Tezspire
Asthma Phase 3 · NCT06023589 Recruiting
Durvalumab
FDA approved May 2017 · Imfinzi
Triple Negative Breast Neoplasms Phase 1/2 · NCT03742102 Active not recruiting
Capivasertib
FDA approved Nov 2023 · Truqap
Triple Negative Breast Neoplasms Phase 1/2 · NCT03742102 Active not recruiting
Benralizumab Prefilled Syringe Asthma; Eosinophilic Phase 4 · NCT04565483 Completed
FDC laroprovstat/Rosuvastatin 2 Hypercholesterolemia Phase 3 · NCT07930507 Not yet recruiting
Rosuvastatin 2 Dyslipidaemia Phase 2/3 · NCT06834932 Active not recruiting
Rosuvastatin 1 Dyslipidaemia Phase 2/3 · NCT06834932 Active not recruiting
Endocrine therapy Advanced Breast Cancer Phase 3 · NCT07683754 Recruiting
FDC laroprovstat/Rosuvastatin 1 Hypercholesterolemia Phase 3 · NCT07930507 Not yet recruiting
Laroprovstat Hypercholesterolemia Phase 3 · NCT07930507 Not yet recruiting

Also used in these trials (approved or third-party drugs, not AZN's own candidates): Clopidogrel Bisulfate, Docetaxel Anhydrous, Carboplatin, Rivaroxaban, Obinutuzumab, Paclitaxel, Palbociclib, Pembrolizumab, Pertuzumab, Venetoclax, Trastuzumab, Adjuvant durvalumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

AZN holds $8.2B in cash and short-term investments and its operations are currently cash-flow neutral or positive.

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AZN files for a raise →

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-11-06
filed 2026-11-10
Sharma Mani
Award (A) 1 $186.24 19,292
2026-10-06
filed 2026-10-08
Sharma Mani
Award (A) 2 $159.80 19,291
2026-09-08
filed 2026-09-11
Sharma Mani
Award (A) 1 $162.60 19,289
2026-08-08
filed 2026-09-11
Sharma Mani
Purchase (P) 20 $160.57 19,288
2026-08-06
filed 2026-08-07
Sharma Mani
Award (A) 2 $163.34 19,267

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full AZN picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AZN and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.